- Home
- STRS vs ADAP Comparison
STRS vs ADAP Comparison
Compare STRS & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRS
- ADAP
- Stock Information
- Founded
- STRS 1992
- ADAP 2008
- Country
- STRS United States
- ADAP United Kingdom
- Employees
- STRS N/A
- ADAP N/A
- Industry
- STRS Homebuilding
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- STRS Real Estate
- ADAP Health Care
- Exchange
- STRS Nasdaq
- ADAP Nasdaq
- Market Cap
- STRS 218.2M
- ADAP 212.3M
- IPO Year
- STRS N/A
- ADAP 2015
- Fundamental
- Price
- STRS $21.54
- ADAP $0.60
- Analyst Decision
- STRS
- ADAP Strong Buy
- Analyst Count
- STRS 0
- ADAP 4
- Target Price
- STRS N/A
- ADAP $2.79
- AVG Volume (30 Days)
- STRS 6.7K
- ADAP 2.1M
- Earning Date
- STRS 11-13-2024
- ADAP 11-13-2024
- Dividend Yield
- STRS N/A
- ADAP N/A
- EPS Growth
- STRS N/A
- ADAP N/A
- EPS
- STRS 0.19
- ADAP N/A
- Revenue
- STRS $48,157,000.00
- ADAP $175,041,000.00
- Revenue This Year
- STRS N/A
- ADAP $204.91
- Revenue Next Year
- STRS N/A
- ADAP N/A
- P/E Ratio
- STRS $123.12
- ADAP N/A
- Revenue Growth
- STRS 83.12
- ADAP 146.27
- 52 Week Low
- STRS $20.30
- ADAP $0.43
- 52 Week High
- STRS $30.66
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- STRS 32.96
- ADAP 37.29
- Support Level
- STRS $24.61
- ADAP $0.57
- Resistance Level
- STRS $25.56
- ADAP $0.61
- Average True Range (ATR)
- STRS 0.88
- ADAP 0.04
- MACD
- STRS -0.40
- ADAP -0.00
- Stochastic Oscillator
- STRS 0.00
- ADAP 27.46
About STRS Stratus Properties Inc.
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the acquisition, entitlement, development, management, operation and sale of commercial, multi- and single-family residential real estate properties, located in the Austin Texas area and other select markets in Texas. It operates its business through two segments namely, Real Estate Operations and Leasing Operations.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.